{"id":411846,"date":"2025-12-11T00:30:00","date_gmt":"2025-12-10T23:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/nuevas-perspectivas-en-la-terapia-de-primera-linea\/"},"modified":"2025-12-10T21:16:05","modified_gmt":"2025-12-10T20:16:05","slug":"nuevas-perspectivas-en-la-terapia-de-primera-linea","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/nuevas-perspectivas-en-la-terapia-de-primera-linea\/","title":{"rendered":"Nuevas perspectivas en la terapia de primera l\u00ednea"},"content":{"rendered":"\n<p><strong>En la <em>Conferencia Mundial sobre C\u00e1ncer de Pulm\u00f3n (CMCP<\/em> 2025) de la IASLC celebrada este a\u00f1o en Barcelona, se present\u00f3 un p\u00f3ster sobre el estudio FLAURA2, que present\u00f3 nuevos datos sobre la terapia de combinaci\u00f3n con osimertinib en el c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) de primera l\u00ednea con mutaci\u00f3n del EGFR (EGFRm).<em> <\/em>El estudio demostr\u00f3 que<em> <\/em>osimertinib en combinaci\u00f3n con quimioterapia consistente en pemetrexed con cisplatino o carboplatino reduc\u00eda el riesgo de muerte en un 23% en comparaci\u00f3n con la monoterapia, con efectos secundarios generalmente manejables.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fnuevas-perspectivas-en-la-terapia-de-primera-linea%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>En la Conferencia Mundial sobre C\u00e1ncer de Pulm\u00f3n (CMCP 2025) de la IASLC celebrada este a\u00f1o en Barcelona, se present\u00f3 un p\u00f3ster sobre el estudio FLAURA2, que present\u00f3 nuevos datos&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fnuevas-perspectivas-en-la-terapia-de-primera-linea%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411848,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"C\u00e1ncer de pulm\u00f3n con mutaci\u00f3n del EGFR","footnotes":"[{\"id\":\"e88b0f85-a52c-4cc0-be2c-2e37b16bcaa3\",\"content\":\"<a href=\\\"http:\\\/\\\/www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/humanarzneimittel\\\/authorisations\\\/new-medicines.html\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/humanarzneimittel\\\/authorisations\\\/new-medicines.html<\\\/a><br><a href=\\\"http:\\\/\\\/www.ema.europa.eu\\\/en\\\/documents\\\/overview\\\/tagrisso-epar-medicine-overview_en.pdf\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">www.ema.europa.eu\\\/en\\\/documents\\\/overview\\\/tagrisso-epar-medicine-overview_en.pdf<\\\/a>\"}]"},"category":[11483,11475,11424,11336,11552],"tags":[58122,83844,86144,86146,86148,86147,86145],"powerkit_post_featured":[],"class_list":["post-411846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-el-congreso-informa","category-estudios","category-neumologia","category-oncologia","category-rx-es","tag-carboplatino-es","tag-cisplatino","tag-cpnm-egfrm","tag-flaura-2","tag-flaura2","tag-pemetrexed","tag-terapia-combinada-con-osimertinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-25 15:31:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=411846"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411846\/revisions"}],"predecessor-version":[{"id":411849,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411846\/revisions\/411849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/411848"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=411846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=411846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=411846"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=411846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}